尼氟灭酸杂质B | 72633-64-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 尼氟灭酸杂质B
• 英文名称: 2-Oxo-N-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide
• 英文别名: 2-oxo-N-[3-(trifluoromethyl)phenyl]-1H-pyridine-3-carboxamide
• CAS: 72633-64-8
• 化学式: C₁₃H₉F₃N₂O₂
• 分子量: 282.22
• InChiKey: HRAILYWEUPEYQL-UHFFFAOYSA-N

物化性质

• 沸点：
  507.4±50.0 °C(Predicted)
• 密度：
  1.442±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• WGK Germany：
  3

文献信息

• [EN] 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE<br/>[FR] DERIVES 2-PYRIDONE UTILISES COMME INHIBITEURS D'ELASTASE NEUTROPHILE ET UTILISATION DE CEUX-CI
  申请人：ASTRAZENECA AB

  公开号：WO2005026124A1

  公开（公告）日：2005-03-24

  There are provided novel compounds of formula (I), wherein R1, R2, R4, R5, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.

  提供了式（I）的新化合物，其中R1、R2、R4、R5、G1、G2、L、Y和n如规范中定义的那样，以及其光学异构体、消旋体和互变异构体，以及其药学上可接受的盐；以及它们的制备方法、含有它们的组合物以及它们在治疗中的用途。这些化合物是中性粒细胞弹性蛋白酶的抑制剂。
• 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE
  申请人：AstraZeneca AB

  公开号：EP1663974A1

  公开（公告）日：2006-06-07
• [EN] METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF<br/>[FR] MÉTHODES DE TRAITEMENT DE MALADIES ASSOCIÉES À LA XANTHINE OXYDASE AVEC DE L'ACIDE NIFLUMIQUE ET SES DÉRIVÉS
  申请人：BAYLOR COLLEGE MEDICINE

  公开号：WO2021188296A1

  公开（公告）日：2021-09-23

  Provided herein are methods of using niflumic acid and derivatives thereof for treating a disease or condition associated with elevated serum uric levels in a subject. The methods include administering to the subject an effective amount of a pharmaceutical composition as described herein. The disease or condition associated with elevated serum uric levels can include, for example, gout, hyperuricemia, or cardiovascular disease. Also provided herein are methods of reducing serum uric acid levels in a subject and methods for inhibiting xanthine oxidase activity in a cell. Novel pharmaceutical compositions are also provided herein. (I)